Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells

Journal of Nuclear Medicine

Volumn 42, Issue 12, 2001, Pages 1856-1862

  Fueger, B J ^a   Hamilton, G ^a   Raderer, M ^a   Pangerl, T ^a   Traub, T ^a   Angelberger, P ^a   Baumgartner, G ^a   Dudczak, R ^a   Virgolini, I ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy; DOTA lanreotide; Gemcitabine; Somatostatin receptors

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CELL DNA; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; INDIUM; MITOMYCIN C; SOMATOSTATIN RECEPTOR;

APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL COUNT; CELL CYCLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIGAND BINDING; PANCREAS CARCINOMA; PRIORITY JOURNAL; RECEPTOR BINDING; SCINTIGRAPHY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0035662803     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary hormone
2. Somatostatin in the central nervous system: Physiology and pathological modification
3. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney
4. A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides
5. Cloning, functional expression, and pharmacological characterization of a fourth (hSST4) and a fifth (hSST5) human somatostatin receptor subtype
6. Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase
7. Characterization of functional receptors for somatostatin in rat pituitary cells in culture
8. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors
9. 3]-octreotide: The Rotterdam experience with more than 1000 patients
10. 111-DOTA-lanreotide: Biodistribution, safety, and radiation absorbed dose in tumor patients
11. 99mTc-P829
12. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy
13. 1-octreotide in 194 carcinoid patients: Vienna University experience, 1993 to 1998
14. 1]-octreotide: A case history
15. Pancreatic carcinoma
16. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
17. Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo
18. DOTA-lanreotide: A novel somatostatin analog for tumor diagnosis and therapy
19. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
20. Indium-111-labeled low-density lipoprotein binds with higher affinity to the human liver as compared to iodine-123-labeled low-density lipoprotein
21. The attraction of proteins for small molecules and ions
22. Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor
23. Cell cycle dependent induction of apoptosis by somatostatin analog SMS-201-995 in AtT-20 mouse pituitary tumor cells
24. Sandostatin in the management of nonendocrine gastrointestinal and pancreatic disorders: A preliminary study
25. Vapreotide, a new somatostatin analog in the palliative management of obstructive ileus in advanced cancer
26. Somatostatin and somatostatin analogs in oncology
27. Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: A preclinical study
28. Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo
29. 123I-VIP receptor scanning in patients with pancreatic cancer
30. Gemca: A modulator of intracellular nucleotide and deoxynucleotide metabolism
31. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors
32. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus Nl-(2′-tetrahydrofuryl)-5-fluorouracil
33. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors
34. Clinical pharmacokinetics of high-dose mitomycin C
35. Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients
36. An overview of the clinical pharmacology of topotecan